Biopharmas raising money in public or private financings, including: Helsinn.

Biopharmas raising money in public or private financings, including: Astronautx, GSK, Limmatech.

To get ahead in a tough market like the industry now finds itself, companies are advised to know themselves and their business well, better than they probably think they know themselves. A panel of investors at the BioFuture 2023 conference cautioned that CEOs must have a deep understanding of how their companies are differentiated from their competition in order to thrive.

Biopharmas raising money in public or private financings, including: Abionyx, Biohaven, GSK, Kineta, Oncodesign.

Five life science firms from the U.S., Asia and Germany have banded together to launch a Singapore biotech “incubator” called 65LAB in hopes of finding, funding and accelerating promising research from Singapore’s leading academic institutions to commercialization.

Biopharmas raising money in public or private financings, including: ALX Oncology.

Cancer biotech Adlai Nortye Ltd. raised $57.5 million from its U.S. IPO on Nasdaq and $40 million from a concurrent private placement, ringing up $97.5 million in funding to develop its combo immunotherapy pipeline.

Biopharmas raising money in public or private financings, including: Kineta, Ocean, Shorla, Tryp.

Biopharmas raising money in public or private financings, including: Biohaven, Checkpoint, Iambic, Immunome, Immunovant, Kairos, Lexeo, Morphimmune, Recce, Seagen, Shield, Soleno.